Evidence map›Paper›PMID 36651960›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2023

A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer.

Arash Abiri, Theodore Nguyen, Khodayar Goshtasbi, Sina J Torabi, Edward C Kuan, William B Armstrong, Tjoson Tjoa, Yarah M Haidar

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Arash AbiriDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.ORCID http://orcid.org/0000-0003-2656-1060
Theodore NguyenDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.
Khodayar GoshtasbiDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.
Sina J TorabiDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.
Edward C KuanDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.
William B ArmstrongDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.
Tjoson TjoaDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.
Yarah M HaidarDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA. haidary@uci.edu.ORCID http://orcid.org/0000-0003-4211-6979
University of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008620 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI GOLDIN, ALAN L · 1999 to 2023
$8.1M
NCI NIH HHS P30 CA062203NIGMS NIH HHS T32 GM008620NIGMS NIH HHS T32GM008620
6 · The paper itself

Abstract

purposeThis study aimed to evaluate the efficacy of different treatment combinations on patient survival in intermediate-risk differentiated thyroid cancer (DTC).

methodsThe 2004-2017 National Cancer Database was queried for intermediate-risk papillary (PTC), follicular (FTC), or Hurthle cell (HTC) thyroid cancer patients. Four treatments were analyzed using Kaplan Meier and multivariable Cox regression: surgery, surgery with adjuvant radioiodine ablation (S + RAI), surgery with adjuvant thyroid-stimulating hormone suppression therapy (S + THST), and S + RAI + THST. Kaplan-Meier and multivariable Cox proportional-hazards analyses evaluated treatment-associated overall survival (OS).

resultsOf 65,736 patients, 72.2% were female and the average age was 45.4 ± 15.4 years. The 10-year OS rates for PTC, FTC, and HTC were 93.2%, 85.2%, and 78.5%, respectively. S + RAI + THST exhibited higher OS than surgery alone and S + RAI (all p < 0.05). Compared to surgery alone, S + RAI + THST demonstrated reduced mortality in PTC (Hazard Ratio [HR]: 0.628, p < 0.001), FTC (HR: 0.490, p < 0.001), and HTC (HR: 0.520, p = 0.006). Similarly, adjuvant RAI + THST reduced mortality regardless of lymphovascular invasion (HR: 0.490, p < 0.001), N1a (HR: 0.570, p < 0.001) or N1b metastasis (HR: 0.621, p < 0.001), or positive margin status (HR: 0.572, p < 0.001).

conclusionsTreatment combinations demonstrated varying efficacies in intermediate-risk DTC depending on histology and tumor characteristics, with S + RAI + THST exhibiting the greatest treatment response.

Indexed as

AdenocarcinomaThyroid NeoplasmsAdenoma, OxyphilicAdultFemaleHumansIodine RadioisotopesMaleMiddle AgedRadiotherapy, AdjuvantRetrospective StudiesThyroidectomyTreatment OutcomeIodine RadioisotopesDifferentiated thyroid cancerFollicular thyroid cancerHurthle cell thyroid cancerOutcomesPapillary thyroid cancerTreatment

Identifiers

PMID36651960
PMCPMC12582169
OpenAlexW4317234384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.